Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients’ adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with...

Descripción completa

Detalles Bibliográficos
Autores principales: Yone, Eric W Pefura, Kengne, André P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520460/
https://www.ncbi.nlm.nih.gov/pubmed/23248575
http://dx.doi.org/10.2147/HIV.S24432
_version_ 1782252792075780096
author Yone, Eric W Pefura
Kengne, André P
author_facet Yone, Eric W Pefura
Kengne, André P
author_sort Yone, Eric W Pefura
collection PubMed
description An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients’ adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.
format Online
Article
Text
id pubmed-3520460
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35204602012-12-17 Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment Yone, Eric W Pefura Kengne, André P HIV AIDS (Auckl) Review An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients’ adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments. Dove Medical Press 2012-12-05 /pmc/articles/PMC3520460/ /pubmed/23248575 http://dx.doi.org/10.2147/HIV.S24432 Text en © 2012 Pefura Yone and Kengne, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Yone, Eric W Pefura
Kengne, André P
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_full Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_fullStr Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_full_unstemmed Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_short Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
title_sort clinical utility and consumer considerations for the use of once-daily nevirapine extended release for hiv infection treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520460/
https://www.ncbi.nlm.nih.gov/pubmed/23248575
http://dx.doi.org/10.2147/HIV.S24432
work_keys_str_mv AT yoneericwpefura clinicalutilityandconsumerconsiderationsfortheuseofoncedailynevirapineextendedreleaseforhivinfectiontreatment
AT kengneandrep clinicalutilityandconsumerconsiderationsfortheuseofoncedailynevirapineextendedreleaseforhivinfectiontreatment

Ejemplares similares